FIELD: medicine.
SUBSTANCE: the present innovation deals with infecting macrophages and cells of macrophagous cell lines with pathogenic microorganisms, their treatment with medicinal remedies followed by gamma-irradiation, immunization of disease-resistant and disease-sensitive animal lines and infecting vaccinated animals with alive pathogenic microorganisms that leads to improved immunity to pathogenic microorganisms.
EFFECT: higher efficiency.
4 cl, 1 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MYCOBACTERIUM TUBERCULOSIS VACCINE | 2009 |
|
RU2473365C1 |
| COMPOSITION FOR STIMULATING DENDRITIC CELL MATURATION, CONTAINING HYBRID PROTEIN RV2299C/ESAT-6 | 2017 |
|
RU2733886C2 |
| TUBERCULOSIS VACCINE WITH IMPROVED STRENGTH | 2004 |
|
RU2342400C2 |
| USE OF MONOMYCOLYL GLYCEROL (MMG) AS ADJUVANT | 2008 |
|
RU2479317C2 |
| COMBINATION OF RECOMBINANT MICROBACTERIUM AND BIOLOGICALLY ACTIVE AGENT AS VACCINE | 2005 |
|
RU2495677C2 |
| METHOD OF PRODUCING RECOMBINANT VACCINE | 2010 |
|
RU2444570C1 |
| VACCINE BASED ON B-CELLS, LOADED WITH LIGANDS OF T-CELLS-NATURAL KILLERS AND ANTIGEN | 2006 |
|
RU2420311C2 |
| METHOD FOR PREPARING AUTOLOGOUS TUBERCULOSIS VACCINE | 2008 |
|
RU2372936C1 |
| COMBINATION PREPARATION FOR INCREASING POTENCY OF VACCINE (VERSIONS) | 2008 |
|
RU2491090C2 |
| POLYANTIGENIC VACCINE FOR PREVENTING AND ADJUNCTIVE TREATMENT OF TUBERCULOSIS | 2019 |
|
RU2724896C1 |
